Skip to main content
Premium Trial:

Request an Annual Quote

Lunaphore Technologies, Cell Signaling Technology Partner on Antibody-Based Spatial Proteomics

NEW YORK – Lunaphore Technologies and Cell Signaling Technology said on Wednesday that they have partnered on antibody-based spatial protein analysis.

Under the terms of the deal, the firms will enable the use of CST's antibodies on Lunaphore's Comet platform. Danvers, Massachusetts-based CST offers more than 1,700 immunohistochemistry-validated antibodies, which will be detected by fluorescent secondary antibodies on Comet.

Financial and other terms of the agreement were not disclosed.

Switzerland-based Lunaphore shifted its focus in 2022 to high-plex spatial proteomics. The Comet platform can stain as many as 40 proteins per sample. In April, the firm signed an agreement with Abcam to comarket that company's antibody portfolio for use on Comet.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.